EpiCast Report: AgeRelated Macular Degeneration Epidemiology Forecast to 2026 [Report Updated: 01112017] Prices from USD $3995
EpiCast Report: AgeRelated Macular Degeneration Epidemiology Forecast to 2026
Summary
Agerelated macular degeneration AMD is a progressive eye condition that is characterized by the gradual deterioration of the macula, which is the area of the retina responsible for central vision. AMD is the most common cause of significant irreversible vision loss among the elderly.
GlobalData epidemiologists utilized national databases and robust peerreviewed journal articles to build the forecast for the total prevalent cases including both diagnosed and undiagnosed as well as the diagnosed incident cases of AMD, early AMD, late AMD, late dry AMD, late wet AMD, and large drusen in the 7MM.
In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases symptomatic of hand OA will increase from 17,948,101 cases in 2016 to 20,413,591 cases in 2026 at an annual growth rate AGR of 1.37%, the diagnosed prevalent cases symptomatic of knee OA will increase from 15,235,201 cases in 2016 to 17,641,626 cases in 2026 at an AGR of 1.58%, and the diagnosed prevalent cases symptomatic of hip OA will increase from 3,361,141 cases in 2016 to 3,867,480 cases in 2026 at an AGR of 1.51%.
The total prevalent cases of AMD in the 7MM will increase from 71,787,702 cases in 2016 to 82,997,296 cases in 2026, at an Annual Growth Rate AGR of 1.56% over the forecast period. Throughout the forecast period, Japan will have the highest number of total prevalent cases of AMD, followed by Italy. The total prevalent cases of AMD in Japan and Italy combined will make up approximately 39.28% of the total prevalent cases of AMD in the 7MM. GlobalData epidemiologists attribute the growth in the total prevalent cases of AMD in the 7MM to the changing population demographics in the respective markets.
Scope
The Agerelated Macular Degeneration AMD EpiCast Report provides an overview of the risk factors and global trends of AMD in the seven major markets 7MM: US, France, Germany, Italy, Spain, UK, and Japan.
The report also includes a 10year epidemiological forecast for the total prevalent cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD, all of which are segmented by sex and age ages 50 years and older in these markets. GlobalData epidemiologists also provided the diagnosed incident cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD, all of which are segmented by sex and age ages 50 years and older. Additionally, the report includes a 10year epidemiological forecast for the total prevalent cases and diagnosed incident cases of large drusen 125 m segmented by sex and age ages 50 years and older in these markets.
The AMD epidemiology report is written and developed by Masters and PhDlevel epidemiologists.
The EpiCast Report is indepth, high quality, transparent and marketdriven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
The AMD EpiCast report will allow you to
Develop business strategies by understanding the trends shaping and driving the global AMD market.
Quantify patient populations in the global AMD market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AMD therapeutics in each of the markets covered.
Understand magnitude of AMD population by type.
Original Article: EpiCast Report: AgeRelated Macular Degeneration Epidemiology Forecast to 2026 [Report Updated: 01112017] Prices from USD $3995
